What is the therapeutic role and blood glucose lowering capability of bromocriptine and cholestyramine for the treatment of Type 2 diabetes?

In the 15 or so years since bromocriptine and cholestyramine were approved for the treatment of hyperglycemia in T2DM, I have never prescribed them for this indication. I also have very rarely used other FDA-approved glucose-lowering agents including meglitinides, alpha-glucosidase inhibitors and am...

Cycloset is a weakly effective drug, will lower A1C levels by 0.3 to 0.5 percent when taken alone or in combination with a sulfonylurea. It is different than bromocriptine since it is in a rapidly released formulation takes within two hours of waking up.

However, it lowers insulin resistance and in ...